Prosecution Insights
Last updated: April 19, 2026

Examiner: LEE, WILLIAM Y

Tech Center 1600 • Art Units: 1623 1629

This examiner grants 48% of resolved cases

Performance Statistics

47.8%
Allow Rate
-12.2% vs TC avg
754
Total Applications
+33.9%
Interview Lift
1153
Avg Prosecution Days
Based on 697 resolved cases, 2023–2026

Rejection Statute Breakdown

1.1%
§101 Eligibility
12.5%
§102 Novelty
42.7%
§103 Obviousness
20.0%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
17634420 REGENERATING FUNCTIONS AND PHENOTYPES OF CONNECTIVE TISSUE THROUGH NPAS2 SUPPRESSION Final Rejection The Regents of the University of California
17727519 Method of Treating Colorectal Cancers Using a PKC Inhibitor Non-Final OA UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.
17936179 23-O-ACETYLALISOL B AS A NOVEL THERAPEUTIC AGENT FOR CORONAVIRUS INDUCED SEVERE ACUTE RESPIRATORY SYNDROME Final Rejection The University of Hong Kong
18784718 OPHTHALMIC COMPOSITION Non-Final OA Sydnexis, Inc.
18759282 ORAL CANNABINOID PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING INFLAMMATORY GASTROINTESTINAL DISORDERS Non-Final OA Curio IP, LLC
17757609 METHODS FOR INHIBITION OF ALPHA-SYNUCLEIN mRNA USING SMALL MOLECULES Final Rejection Rutgers, The State University of New Jersey
18735095 COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF Non-Final OA ELEVATEBIO TECHNOLOGIES, INC.
17799641 MONO AND COMBINATION THERAPIES WITH ULK1/2 INHIBITORS Non-Final OA SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
17399015 ANTIFUNGAL AGENTS USED IN COMBINATION Non-Final OA Scynexis, Inc.
18438060 METHODS OF TREATING CONGENITAL ADRENAL HYPERPLASIA Non-Final OA Spruce Biosciences, Inc.
17578149 METHODS OF TREATING CONGENITAL ADRENAL HYPERPLASIA Non-Final OA Spruce Biosciences, Inc.
18125474 COMPOSITIONS AND METHODS FOR REDUCING GREENHOUSE GAS Final Rejection Rumin8 Pty Ltd
18221295 INDOMETHACIN PHARMACEUTICAL COMPOSITION Non-Final OA FULTON MEDICINALI S.P.A.
17756095 DOSING REGIMENS FOR A PROTEIN KINASE C INHIBITOR Non-Final OA IDEAYA BIOSCIENCES, INC.
17616313 METHODS FOR TREATING PULMONARY ARTERIAL HYPERTENSION Final Rejection ACTELION PHARMACEUTICALS LTD
17765934 PHARMACEUTICAL COMPOSITION COMPRISING ENZALUTAMIDE Non-Final OA Synthon B.V.
17613467 A THERAPEUTIC APPROACH FOR TREATING NON-INFECTIOUS OCULAR IMMUNOINFLAMMATORY DISORDERS Final Rejection The Schepens Eye Research Institute, Inc.
18037123 COMBINATION THERAPY FOR THE TREATMENT OF A LIVER DISEASE Final Rejection INVENTIVA
18295125 MAGNETIC RESONANCE SPECTROSCOPY TO CALIBRATE AND SELECT DOSES, FORMULATIONS, AND DEVICES FOR INTRA-NASAL ADMINISTRATION OF N-ACETYLCYSTEINE Final Rejection Neuronasal, Inc.
17985253 BUPRENORPHINE DOSING REGIMENS Non-Final OA Indivior UK Limited
17981673 DRY POWDER INHALATION DRUG PRODUCTS EXHIBITING MOISTURE CONTROL PROPERTIES AND METHODS OF ADMINISTERING THE SAME Non-Final OA GLAXO GROUP LIMITED
17923729 USE OF BENZISOSELAZOLE DERIVATIVE FOR ANTI-CORONAVIRUS AND CONTROL OF INTERSTITIAL LUNG DISEASE (ILD) RELATED TO CORONAVIRUS Non-Final OA SHANGHAI YUANXI MEDICINE CORP.
17922921 NOVEL EXTENDED RELEASE COMPOSITION OF TOFACITINIB, ITS DERIVATIVES AND SALTS Final Rejection Zim Laboratories Limited
17968253 CO-CRYSTALS OF TRAMADOL AND COXIBS Non-Final OA ESTEVE PHARMACEUTICALS, S.A.
17519844 STABLE CANNABINOID FORMULATIONS Non-Final OA Fresh Cut Development, LLC
17367876 STABLE CANNABINOID FORMULATIONS Non-Final OA Fresh Cut Development LLC
17601148 USE OF GINKGO TERPENE LACTONE IN PREPARING DRUG FOR PREVENTING AND/OR TREATING GUILLAIN-BARRE-STROHL SYNDROME Non-Final OA CHENGDU BAIYU PHARMACEUTICAL CO., LTD.
17333525 PRODUCT AND METHOD FOR TREATING DIARRHEA Non-Final OA Maregade RX, LLC
17252481 PLASMALOGEN-CONTAINING COMPOSITION Final Rejection MARUDAI FOOD CO., LTD.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month